
Boehringer and Re-Vana partner on long-acting ophthalmic therapies
Boehringer Ingelheim and Re-Vana Therapeutics have announced a strategic collaboration and license agreement to develop first-in-class extended-release therapies for eye diseases. Treating ophthalmic diseases often requires frequent injections directly into the eye, which can be very burdensome for patients. Re-Vana’s drug delivery technology is designed to release treatments slowly over… Read More
